Efficacy and safety of switching from insulin glargine to insulin degludec in young people with type 1 diabetes

Endocrine Journal

Volumn 63, Issue 2, 2016, Pages 159-167

  Urakami, Tatsuhiko ^a   Kuwabara, Remi ^a   Aoki, Masako ^a   Okuno, Misako ^a   Suzuki, Junichi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Basal bolus therapy; Glycemic control; Insulin degludec; Type 1 diabetes; Young people

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN GLARGINE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; JAPANESE (PEOPLE); MALE; NOCTURNAL HYPOGLYCEMIA; CIRCADIAN RHYTHM; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION; DRUG EFFECTS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN GLARGINE; INSULIN, LONG-ACTING; MALE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84959352911     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ15-0245     Document Type: Article

References (29)

1. Court JM, Cameron FJ, Berg-Kelly K, Swift PG (2009) Diabetes in adolescents. ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. Pediatr Diabetes 10 (Suppl 12): 185-194.
2. (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329: 977-986.
3. Writing Team for the Diabetes Control and Complications Trial Research Group/Epidemiology of Diabetes Interventions and Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287: 2563-2569.
4. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, et al. (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643-2653.
5. Clarke W, Jones T, Rewers A, Dunger D, Klingensmith GJ (2009) Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes 10 Suppl 12: 134-145.
6. Wolfsdorf J, Craig ME, Daneman D, Dunger D, Edge J, et al. (2009) Diabetes ketoacidosis in children and adolescents with diabetes. ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. Pediatr Diabetes 10 Suppl 12: 118-133.
7. Bangstad H-J, Danne T, Deeb L, Jarosz-Chobot P, Urakami T, et al. (2009) Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes 10 Suppl 12: 82-99.
8. Urakami T, Morimoto S, Kubota S, Funaki S, Harada K (2007) Usefulness of the long-acting insulin analogue glargine in basal-bolus therapy for Japanese children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 20: 807-815.
9. Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, et al. (2007) Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 30: 2447-2452.
10. Urakami T, Kuwabara R, Habu M, Komiya K, Nagano N, et al. (2012) Comparison of the injection frequencies employed and basal-to-total insulin dose ratios obtained when glargine and detemir are used in children with type 1 diabetes mellitus treated by basal-bolus therapy. Diabetol Int 3: 75-79.
11. Urakami T, Naito Y, Seino Y (2014) Insulin glargine in pediatric patients with type 1 diabetes in Japan. Pediatr Int 56: 822-828.
12. Jonassen I, Havelund S, Ribel U, Hoeg-Jensen T, Steensgard DB, et al. (2010) Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation. Diabetes 59 Suppl 1: A11 (abstract).
13. Heise T, Nosek L, Bøttchet SG, Hastrup H, Haahr H (2011) Ultra-long-acting insulin degludec has a twofold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetes 60 Suppl 1: A11 (abstract).
14. Heller S, Buse J, Fisher M, Garg S, Marre M, et al. (2012) Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomized, openlabel, treat-to-target non-inferiority trial. Lancet 379: 1489-1497.
15. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, et al. (2012) Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomized, openlabel, treat-to-target non-inferiority trial. Lancet 379: 1498-1507.
16. Biester T, Blaesig S, Remus K, Aschemeier B, Kordonouri O, et al. (2014) Insulin degludec’s ultralong pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Pediatr Diabetes 15: 27-33.
17. Thalange N, Deeb L, Iotova V, Kawamura T, Klingensmith G, et al. (2015) Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatr Diabetes 16: 164-176.
18. Rewers M, Pihoker C, Donaghue K, Hanas R, Swift P, et al. (2009) Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 10 Suppl 12: 71-81.
19. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV (1986) Impaired insulin action in puberty: a contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 315: 215-219.
20. Bloch CA, Clemons P, Sperling MA (1987) Puberty decreases insulin sensitivity. J Pediatr 110: 481-487.
21. Pankowska E, Szypowska A, Lipka M (2008) Basal insulin and total daily insulin dose in children with type 1 diabetes using insulin pumps. Pediatr Diabetes 9: 208-213.
22. Urakami T, Kuwabara R, Habu M, Okuno M, Suzuki J, et al. (2014) Basal insulin requirement of youth with type 1 diabetes differs according to age. J Diabetes Investig 5: 442-444.
23. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, et al. (2012) Insulin degludec: four times lower phar-macodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 14: 859-864.
24. Ratner RE, Gough SC, Mathieu C, Del Prato S, Bode B, et al. (2013) Hypoglycemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 15: 175-184.
25. Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, et al. (2011) Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 34: 661-665.
26. Bode BW, Buse JB, Fisher M, Garg SK, Marre M, et al. (2013) Insulin degludec improves glycemic control with lower nocturnal hypoglycemia risk than insulin glargine in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med 30: 1293-1297.
27. Kusunoki Y, Katsuno T, Miyakoshi K, Ikawa T, Nakae R, et al. (2013) Effects of switching from insulin degluudec in patients with type 1 diabetes mellitus. Diabetes Ther 4: 461-472.
28. Nakamura T, Sakaguchi K, So A, Nakajima S, Takabe M, et al (2015) Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicenter, randomized, crossover study. Diabetologia 58: 2013-2019.
29. Yamada K, Nakayama H, Sato S, Tajiri Y, Kaku H, et al. (2014) A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec among patients with type 1 diabetes. Diabetol Int 5: 74-77.